Recombinant Human PD-1 Fc Chimera Protein, CF 1086-PD-050 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human PD-1 Fc Chimera Protein, CF
CompanyR&D Systems, a Bio-Techne Brand
Price $438.00Supplier Page View Company Product Page
Catalog Number1086-PD-050
SpeciesHuman
Size50 ug (also 1 mg)
FormatLyophilized from a 0.2 µm filtered solution in PBS
Molecule NamePD-1
NCBI Full Gene Nameprogrammed cell death 1
NCBI Gene AliaseshPD-l, CD279, PD-1, PD1, hSLE1, SLEB2, hPD-1
Purity>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
Molecular WeightObserved: 60 - 70 kDa, under reducing conditions.
Theoretical: 42.6 kDa (monomer)
ApplicationsBinding Activity
Conjugate/TagUnconjugated
Source/Expression SystemNS0-derived Recombinant Human PD-1 Fc Chimera Protein, CF
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Targeting the noncanonical function of metabolic enzyme PHGDH in driving PD-L1 expression and cancer immune evasionCell Reports MedicineApril 21, 2026Juan Liu, Weiwei Wang, Yvonne Sun, Shan Huang, Arnav Borole, Haiyan Zheng, Wenwei Hu, Zhaohui FengHY-101494 Flag peptide,Sigma-Aldrich,Cat# F4799 Recombinant human PD-1 Fc chimera protein,R&D Systems,Cat# 1086-PD-050 Recombinant mouse PD-1 Fc chimera protein,R&D Systems,Cat# 1021-PD-050 Human IL-2,BioLegend,Cat# 589102 Mouse

(2) LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinomaCell Death DiscovJune 7, 2025Yuxuan Li, Jie Zhu, Fengguang Zhai, Yidong Ge, Ziqing Zhan, Shuyan Wang, Lili Kong, Jianan Zhao, Lecheng Hu, Siyuan Wang, et al.assay A total of 1 × 106 cells were incubated with 5 μg/ml recombinant human PD-1 FC chimeric protein (#1086-PD-050, R&D Systems, USA) for 30 min at room temperature. Subsequently, the cells were washed with staining

(3) N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycanSignal Transduct Target TherApril 28, 2025Li Li, Jiajia Wu, Weiqian Cao, Wei Zhang, Qi Wu, Yaxu Li, Yanrong Yang, Zezhi Shan, Zening Zheng, Xin Ge, et al.ConA-Biotin (Xi’an Qiyue Biology, Cat# R-FC-005). Recombinant proteins human PD-1 Fc chimera (Cat# 1086-PD-050) and human Siglec-10 Fc chimera (Cat# 2130-SL-050) were purchased from R&D Systems. Western blotting For

(4) Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulationNature communicationsJanuary 3, 2025Hwang HJ, Kang D, Shin J, Jung J, Ko S, Jung KH, Hong SS, Park JE, Oh MJ, An HJ, et al.

(5) BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinomaCellular and Molecular Life SciencesDecember 1, 2024Zongdong Yu, Xiang Wu, Jie Zhu, Huan Yan, Yuxuan Li, Hui Zhang, Yeling Zhong, Man Lin, Ganghui Ye, Xinming Li, et al.binding assay Cells (1 × 106) were incubated with 5 μg/ml of recombinant human PD-1 FC chimera protein (#1086-PD-050, R&D Systems, USA) for 30 min at room temperature. After washing with staining buffer, the cells were

(6) Preclinical comparison of prolgolimab, pembrolizumab and nivolumabScientific reportsOctober 4, 2024Gordeev A, Vaal A, Puchkova M, Smirnova I, Doronin A, Znobishcheva A, Zhmudanova D, Aleksandrov A, Sukchev M, Imyanitov E, et al.

(7) The branched N-glycan of PD-L1 predicts immunotherapy responses in patients with recurrent/metastatic HNSCCOncogenesisOctober 2, 2024Huang HC, Huang YL, Chen YJ, Wu HY, Hsu CL, Kao HF, Liao BC, Hsieh MS, Lin NY, Liao YH, et al.

(8) Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruptionNature immunologyOctober 1, 2024Pereira Ribeiro S, Strongin Z, Soudeyns H, Ten-Caten F, Ghneim K, Pacheco Sanchez G, Xavier de Medeiros G, Del Rio Estrada PM, Pelletier AN, Hoang T, et al.

(9) Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interactionCell reportsSeptember 24, 2024Robinson MA, Kennedy A, Orozco CT, Chen HC, Waters E, Giovacchini D, Yeung K, Filer L, Hinze C, Lloyd C, et al.

(10) CircRHBDD1 promotes immune escape via IGF2BP2/PD-L1 signaling and acts as a nanotherapeutic target in gastric cancerJournal of translational medicineJuly 30, 2024Li Y, Wang Z, Gao P, Cao D, Dong R, Zhu M, Fei Y, Zuo X, Cai J.

(11) Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancerBritish journal of cancerJuly 1, 2024Jeong H, Koh J, Kim S, Song SG, Lee SH, Jeon Y, Lee CH, Keam B, Lee SH, Chung DH, et al.

(12) Let's Get Rolling: Precise Control of Microfluidic Assay Conditions to Recapitulate Selectin‐Mediated Rolling Interactions of the Leukocyte Adhesion CascadeCurrent ProtocolsApril 5, 2024Zeinab Amoabediny, Aman Mittal, Subham Guin, Alexander Buffone JrVCAM-1 (R&D Systems Catalog No. ADP5-050) OR Recombinant Human PD-1 Fc Chimeras (R&D Systems Catalog No. 1086-PD-050) Human Recombinant CXCL12 (ThermoFisher Scientific Catalog No. A42506) Flexiperm gaskets (Sarstedt Catalog

(13) A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory AntibodiesCancersNovember 9, 2023Manna L, Rapuano Lembo R, Yoshioka A, Nakamura K, Passariello M, De Lorenzo C.

(14) Clinical Staphylococcus aureus inhibits human T-cell activity through interaction with the PD-1 receptormBioOctober 31, 2023Mellergaard M, Skovbakke SL, Jepsen SD, Panagiotopoulou N, Hansen ABR, Tian W, Lund A, Høgh RI, Møller SH, Guérillot R, et al.

(15) The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1CellsSeptember 23, 2023Erlichman N, Meshel T, Baram T, Abu Raiya A, Horvitz T, Ben-Yaakov H, Ben-Baruch A.

(16) Granulocyte-Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint BlockadeCancer immunology researchAugust 3, 2023Li X, Li J, Zheng Y, Lee SJ, Zhou J, Giobbie-Hurder A, Butterfield LH, Dranoff G, Hodi FS.

(17) Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic targetProceedings of the National Academy of SciencesMarch 14, 2023Junzhi Zhou, Xiaohe Ma, Xingrui He, Beiying Chen, Jiao Yuan, Zhemin Jin, Lijing Li, Zhiguo Wang, Qian Xiao, Yafei Cai, et al.(PBS). Cells were incubated with 5 μg/mL recombinant human PD-1 FC chimera protein (1:100) (R&D Systems; 1086-PD-050,) at room temperature for 1 h. The cells were washed with PBS buffer three times before incubating with

(18) The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80The EMBO journalMarch 1, 2023Kennedy A, Robinson MA, Hinze C, Waters E, Williams C, Halliday N, Dovedi S, Sansom DM.flow cytometry. Flow cytometry Antibodies and detection reagents APC‐conjugated proteins: PD‐1‐Ig (Bio‐Techne, 1086‐PD‐050), anti‐PD‐L1 (Durvalumab) and CTLA‐4 Ig (Abatacept & Belatacept) were generated using the APC Conjugation Kit—Lightning‐Link

(19) Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody developmentScientific reportsOctober 22, 2022Phakham T, Boonkrai C, Wongtangprasert T, Audomsun T, Attakitbancha C, Saelao P, Muanwien P, Sooksai S, Hirankarn N, Pisitkun T.

(20) Regulation of PD-L1 through direct binding of cholesterol to CRAC motifsScience advancesAugust 26, 2022Wang Q, Cao Y, Shen L, Xiao T, Cao R, Wei S, Tang M, Du L, Wu H, Wu B, et al.obtained from Cell Signaling Technology (Danvers, MA, USA). Recombinant human PD-1 FC chimera protein (1086-PD050) was purchased from R&D Systems (Minneapolis, MN, USA). MG132, MCD, CHX, and simvastatin were obtained

Write a Review

(1)

7/8/20191086-PD (PD-1 Fc) Is Bound by PD-1-Specific Antibodies by ELISA Anonymous ReviewerThe reagent is suitable for ELISA.

Recombinant Human PD-1 Fc Chimera Protein, CF

PD-1 Fc Chimera Protein

PD-1 Fc Chimera Protein

PD-1 Fc Chimera Protein

Recombinant Human PD-1 Fc Chimera Protein, CF from R&D Systems, a Bio-Techne Brand

Description

R&D Systems, a Bio-Techne Brand

Citations (55)

Reviews

Recombinant Human PD-1 Fc Chimera Protein, CF from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map